ABL Bio Inc. (298380.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩40,850 (+0.12%) as of
Key statistics
- Market cap
- 2.29T
- Forward P/E
- 164.06
- Dividend yield
- 0.00%
- 52-week range
- 39,700.00 – 257,500.00
- Beta
- 0.28
- Revenue (TTM)
- 34.28B
- Profit margin
- -229.36%
- Analyst target
- ₩270,000
- Volume
- 247.33k
About ABL Bio Inc.
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seoul, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.